Amgen Urges Adoption Of Balanced Policies For Biosimilars
Chad Pettit Discusses Amgen’s Unique Perspective On Biosimilars
Executive Summary
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.